Compare ALCO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | LCTX |
|---|---|---|
| Founded | 1960 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 255.4M |
| IPO Year | 1994 | 1996 |
| Metric | ALCO | LCTX |
|---|---|---|
| Price | $39.70 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $44.00 | $6.25 |
| AVG Volume (30 Days) | 14.4K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.86 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $31.32 | $0.96 |
| 52 Week High | $45.01 | $2.09 |
| Indicator | ALCO | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 36.60 |
| Support Level | $37.31 | N/A |
| Resistance Level | $40.13 | $1.18 |
| Average True Range (ATR) | 0.81 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 68.51 | 6.30 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.